Clinical Observation Of CAG Regimen On Patients With High Risk Myelodysplastic Syndrome

Objective: To observe the clinical efficacy and adverse reactions of CAG regimenwhich is jiont with low-dose cytarabine, Aclacinomycin and granulocytecolony-stimulating factor in the treatment of high risk myelodysplastic syndrome.Methods: A retrospective analysis of our27patients with previously untreated adult MDSpatients, the were implemented with CAG regimen, according to clinical manifestations,evaluation of the efficacy of the peripheral blood and bone marrow cytology results,follow-up analysis of the overall survival of patients judge CAG regimen the long-termefficacy. Rate compared using Fisher’s exact test was used for statistical.Results: the complete remission rate of27patients was51.8%(14/27), the total effectiverate was70.4%(19/27); compared with age≥60-year-old patients,patients which age <60years has a slightly higher rate at complete remission rate and total efficiency is, but thedifference was not statistically significant (P>0.05). Better prognosis karyotype (goodprognosis karyotype+the prognosis medium) induction treatment of patients and the poorprognosis of patients with total efficiency of11/13and2/8, respectively, after statisticalcomparisons, P<0.05, statistically differences between correlation karyotype and treatmentefficacy. The main adverse reaction to the vast majority of patients can tolerate forsecondary infection and bleeding due to bone marrow suppression, to give timely use ofantibiotics and transfusion support. Patients with underlying diseases than the underlyingdisease, the median survival time is short. Good karyotype in patients with chromosomekaryotype poor overall survival in patients with a long time.Conclusion: The the CAG regimen safe and effective for the treatment of high-risk MDSpatients, the long-term efficacy needs further observation.